Sign In
Buy TBPH
$15.92
+0.340 (+2.18%)
At Close: Jun 03, 2026
5 Small Drug Stocks to Buy as Trump Gets Re-Elected
08:21am, Friday, 08'th Nov 2024
Innovation is at its peak for the Zacks Medical-Drugs industry. MDGL, CORT, CPRX, LRMR and TBPH may prove to be good additions to one's portfolio.
Theravance Biopharma to Report Third Quarter 2024 Financial Results on November 12, 2024
06:00am, Thursday, 24'th Oct 2024
DUBLIN , Oct. 24, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its third quarter 2024 financial results and provide a business update after market close on Tuesday, Novem
DUBLIN , Oct. 18, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced the publication of a sub-study of the pivotal 12-week, random
Invest Alongside Wall Street Legend Seth Klarman: 2 New Stocks He Bought and 1 He Dumped
11:32am, Sunday, 29'th Sep 2024
Enigmatic investing legend Seth Klarman runs the Boston-based Baupost Group hedge fund that has around $27 billion in assets under management.
Theravance Bio (TBPH) Up 2.2% Since Last Earnings Report: Can It Continue?
12:35pm, Wednesday, 04'th Sep 2024
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock?
Theravance Biopharma to Participate in an Upcoming Investor Conference
06:00am, Tuesday, 27'th Aug 2024
DUBLIN , Aug. 27, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference in New York City on
Theravance (TBPH) Q2 Loss Wider Than Expected, Revenues Rise Y/Y
12:01pm, Tuesday, 06'th Aug 2024
Theravance (TBPH) misses second-quarter estimates on both fronts. Increased collaboration revenues from Viatris drive year-over-year top-line performance.
Theravance Biopharma, Inc. (TBPH) Q2 2024 Earnings Call Transcript
07:37pm, Monday, 05'th Aug 2024
Theravance Biopharma, Inc. (NASDAQ:TBPH ) Q2 2024 Earnings Conference Call August 5, 2024 5:00 PM ET Company Participants Rick Winningham - Chief Executive Officer Aine Miller - Head, Development Rhon
Theravance Biopharma (TBPH) Reports Q2 Loss, Lags Revenue Estimates
07:01pm, Monday, 05'th Aug 2024
Theravance Biopharma (TBPH) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.13 per share a year ago.
Theravance Biopharma, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
04:05pm, Monday, 05'th Aug 2024
Q2 2024 YUPELRI® (revefenacin) net sales of $54.5 million, recognized by Viatris, decreased 1% from Q2 2023 1 Viatris collaboration revenue of $14.3 million, increased 4% versus Q2 2023 Partner Viatr
Theravance Biopharma to Participate in an Upcoming Investor Conference
06:00am, Thursday, 25'th Jul 2024
DUBLIN , July 25, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Tuesday, August 6 at 12:00 pm ET (9
Theravance Biopharma to Report Second Quarter 2024 Financial Results on August 5, 2024
06:00am, Monday, 22'nd Jul 2024
DUBLIN , July 22, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its second quarter 2024 financial results and provide a business update after market close on Monday, Augus
Best Momentum Stocks to Buy for July 15th
11:16am, Monday, 15'th Jul 2024
TBPH, HGV, and SPT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 15, 2024.
New Strong Buy Stocks for July 15th
08:21am, Monday, 15'th Jul 2024
TEF, AY, CQP, TBPH, and VIRC have been added to the Zacks Rank #1 (Strong Buy) List on July 15, 2024.
Here's Why You May Invest in Theravance (TBPH) Stock Now
12:31pm, Wednesday, 26'th Jun 2024
Here, we discuss some reasons why investing in Theravance (TBPH) stock now may turn out to be a prudent move.
